SEARCH:   Advanced

Blood, 15 August 2007, Vol. 110, No. 4, pp. 1379-1387. Prepublished online as a Blood First Edition Paper on May 8, 2007; DOI 10.1182/blood-2007-02-076307. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-02-076307v1 110/4/1379    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chang, C. Articles by Deeg, H. J. Search for Related Content PubMed PubMed Citation Articles by Chang, C. Articles by Deeg, H. J. Related Collections Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders ChunKang Chang1,2, Barry E. Storer2,3, Bart L. Scott2,3, Eileen M. Bryant2,3, Howard M. Shulman2,3, Mary E. Flowers2,3, Brenda M. Sandmaier2,3, Robert P. Witherspoon2,3, Richard A. Nash2,3, Jean E. Sanders2,3, Antonio Bedalov2,3, John A. Hansen2,3, Bruce E. Clurman2,3, Rainer Storb2,3, Frederick R. Appelbaum2,3, and H. Joachim Deeg2,3 1 Department of Hematology, Shanghai Sixth People's Hospital, Shanghai JiaoTong University, Shanghai, People's Republic of China; 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 3 University of Washington, Seattle We analyzed outcomes after hematopoietic cell transplantation (HCT) in 257 patients, 3 to 72.7 years old (median, 43 y), with secondary myelodysplastic syndrome (MDS) including those with transformation to acute myeloid leukemia (tAML). Conditioning regimens included high-dose total-body irradiation (TBI)/chemotherapy (n = 83); busulfan (BU)/cyclophosphamide (CY) (BUCY, n = 122; with BU targeting [tBUCY], n = 93); fludarabine (Flu) with tBU (FLUtBU; n = 12); Flu plus 200 cGy TBI (n = 26); and miscellaneous regimens (n = 14). Donors were HLA-identical or partially mismatched family members in 135 and unrelated individuals in 122 patients. Five-year relapse-free survival was highest (43%) and nonrelapse mortality lowest (28%) among tBUCY-conditioned patients. Outcomes were compared with results in 339 patients who received transplants for de novo MDS/tAML, and a multivariate analysis failed to show significant differences in outcome between the 2 cohorts. Relapse probability and relapse-free survival correlated significantly with disease stage (P < .001) and karyotype (P < .001). Relapse incidence was lower (P = .003) and relapse-free survival superior (P = .02) with unrelated donor transplants. The data suggest that overall inferior outcome in patients with secondary MDS/tAML was related to the frequency of high-risk cytogenetics. For both cohorts, transplantation outcomes improved over the time interval studied. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF] M. Bornhauser, U. Oelschlaegel, U. Platzbecker, G. Bug, K. Lutterbeck, M. G. Kiehl, J. Schetelig, A. Kiani, T. Illmer, M. Schaich, et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation Haematologica, November 1, 2009; 94(11): 1613 - 1617. [Abstract] [Full Text] [PDF] N. Kroger, R. Brand, A. van Biezen, A. Zander, J. Dierlamm, D. Niederwieser, A. Devergie, T. Ruutu, J. Cornish, P. Ljungman, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation Haematologica, April 1, 2009; 94(4): 542 - 549. [Abstract] [Full Text] [PDF] M. A. Sekeres, W. M. Schoonen, H. Kantarjian, A. List, J. Fryzek, R. Paquette, and J. P. Maciejewski Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys J Natl Cancer Inst, November 5, 2008; 100(21): 1542 - 1551. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020